AMLX

Amylyx Pharmaceuticals, Inc.

Price Chart

Latest Quote

$13.32

-0.99 (-6.92%)

Current Price

Previous Close	$14.31
Open	$14.25
Day High	$14.47
Day Low	$12.96
Volume	1,684,833

Fetched: 2026-06-05T21:59:51

Stock Information

Shares Outstanding	111.19M
Total Debt	$5.63M
Cash Equivalents	$279.77M
Net Income	$-150.11M
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Market Cap	$1.48B
EPS (TTM)	$-1.48
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.21B
Income	$-150.11M
Book/sh	$2.46
Cash/sh	$2.52
Employees	136

Financial Ratios

Quick Ratio	17.53
Current Ratio	17.85
Debt/Eq	2.06

Returns & Margins

ROA	-38.79%
ROE	-63.26%

Ownership

Insider Ownership	7.92%
Institutional Ownership	105.10%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-10.52
P/B	5.41

Analyst Data

Recommendation	none
Target Price	$23.40

Technical Indicators

SMA20	$13.85
SMA50	$15.23
SMA200	$13.82
RSI	50.29
ATR	0.7573

Shares Float	83.53M
Short Float	16.89%
Short Ratio	12.95
Volatility	-0.16
Rel Volume	1.47

Performance History

Week	-7.18%
Month	-17.06%
Quarter	-3.83%
6 Months	-6.26%
YTD	+16.64%
Year	+170.73%
3 Years	-46.05%
10 Years	-26.29%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$13.32	1,738,200
2026-06-04	$14.31	2,240,400
2026-06-03	$13.20	1,026,800
2026-06-02	$13.29	1,650,900
2026-06-01	$14.07	687,100
2026-05-29	$14.35	923,900
2026-05-28	$14.22	563,700
2026-05-27	$14.07	580,200
2026-05-26	$13.68	674,400
2026-05-22	$13.58	818,500
2026-05-21	$13.93	1,023,300
2026-05-20	$13.61	1,702,300
2026-05-19	$12.74	1,134,400
2026-05-18	$12.86	940,700
2026-05-15	$13.28	997,900
2026-05-14	$13.88	845,700
2026-05-13	$14.58	1,058,500
2026-05-12	$14.44	1,084,700
2026-05-11	$14.88	1,995,100
2026-05-08	$14.73	1,892,500
2026-05-07	$15.20	1,452,100
2026-05-06	$16.06	1,376,800

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

📰 Latest News

A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound

Simply Wall St. • 2026-06-01T15:11:06Z

Amylyx Stock: Why the Full Pipeline Story Matters

MarketBeat • 2026-05-24T12:50:00Z

Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress

Insider Monkey • 2026-05-20T20:42:47Z

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

Motley Fool • 2026-05-19T17:37:19Z

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Motley Fool • 2026-05-19T17:26:23Z

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

MarketBeat • 2026-05-14T05:05:38Z

Amylyx (AMLX) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-08T15:36:07Z

Amylyx Pharmaceuticals Q1 Earnings Call Highlights

MarketBeat • 2026-05-07T13:22:26Z

Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch

MarketBeat • 2026-04-15T20:02:50Z

Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment

Insider Monkey • 2026-03-31T11:34:29Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$0	$124,633,000	$25,441,000	$2,993,000
Cost Of Revenue	$0	$124,633,000	$25,441,000	$2,993,000
Total Revenue	$0	$87,371,000	$380,786,000	$22,230,000
Operating Revenue	$0	$87,371,000	$431,433,000	$27,104,000
Expenses
Total Expenses	$153,291,000	$343,048,000	$341,984,000	$223,571,000
Other Income Expense	$-700,000	$-60,268,000	$-660,000	$-551,000
Other Non Operating Income Expenses	$-700,000	$-1,214,000	$-660,000	$-551,000
Net Non Operating Interest Income Expense	$9,302,000	$13,809,000	$16,155,000	$4,291,000
Operating Expense	$153,291,000	$218,415,000	$316,543,000	$220,578,000
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Other Operating Expenses	-	-	-	-
General And Administrative Expense	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-144,735,000	$-301,743,000	$49,271,000	$-198,375,000
Net Interest Income	$9,302,000	$13,809,000	$16,155,000	$4,291,000
Interest Income	$9,302,000	$13,809,000	$16,155,000	$4,291,000
Normalized Income	$-144,735,000	$-242,748,054	$49,271,000	$-198,375,000
Net Income From Continuing And Discontinued Operation	$-144,735,000	$-301,743,000	$49,271,000	$-198,375,000
Total Operating Income As Reported	$-153,291,000	$-314,731,000	$38,802,000	$-201,341,000
Net Income Common Stockholders	$-144,735,000	$-301,743,000	$49,271,000	$-198,375,000
Net Income	$-144,735,000	$-301,743,000	$49,271,000	$-198,375,000
Net Income Including Noncontrolling Interests	$-144,735,000	$-301,743,000	$49,271,000	$-198,375,000
Net Income Continuous Operations	$-144,735,000	$-301,743,000	$49,271,000	$-198,375,000
Pretax Income	$-144,689,000	$-302,136,000	$54,297,000	$-197,601,000
Special Income Charges	$0	$-59,054,000	$0	-
Interest Income Non Operating	$9,302,000	$13,809,000	$16,155,000	$4,291,000
Operating Income	$-153,291,000	$-255,677,000	$38,802,000	$-201,341,000
Gross Profit	$0	$-37,262,000	$355,345,000	$19,237,000
Per Share
Diluted EPS	-	$-4.43	$0.70	$-3.39
Basic EPS	-	$-4.43	$0.73	$-3.39
Other
Tax Effect Of Unusual Items	$0	$-59,054	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-152,766,000	$-195,719,000	$39,890,000	$-200,854,000
Total Unusual Items	$0	$-59,054,000	$0	-
Total Unusual Items Excluding Goodwill	$0	$-59,054,000	$0	-
Reconciled Depreciation	$525,000	$904,000	$1,088,000	$487,000
EBITDA (Bullshit earnings)	$-152,766,000	$-254,773,000	$39,890,000	$-200,854,000
EBIT	$-153,291,000	$-255,677,000	$38,802,000	$-201,341,000
Diluted NI Availto Com Stockholders	$-144,735,000	$-301,743,000	$49,271,000	$-198,375,000
Tax Provision	$46,000	$-393,000	$5,026,000	$774,000
Restructuring And Mergern Acquisition	$0	$22,851,000	$0	-
Research And Development	$90,404,000	$104,084,000	$128,187,000	$93,450,000
Selling General And Administration	$62,887,000	$114,331,000	$188,356,000	$127,128,000
Diluted Average Shares	-	$68,142,158	$69,991,340	$58,495,587
Basic Average Shares	-	$68,142,158	$67,234,465	$58,495,587
Other Special Charges	-	$36,203,000	-	-
Other Gand A	-	-	-	-

Fetched: 2026-05-30

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$305,259,000	$164,765,000	$433,432,000	$340,607,000
Total Assets	$332,645,000	$193,634,000	$517,454,000	$391,453,000
Total Non Current Assets	$8,974,000	$4,202,000	$52,788,000	$9,320,000
Other Non Current Assets	$3,483,000	$1,470,000	$46,377,000	$1,185,000
Current Assets	$323,671,000	$189,432,000	$464,666,000	$382,133,000
Other Current Assets	$6,604,000	$12,484,000	$14,931,000	$10,113,000
Receivables	$88,000	$447,000	$40,050,000	$15,306,000
Accounts Receivable	$88,000	$447,000	$40,050,000	$15,306,000
Cash Cash Equivalents And Short Term Investments	$316,979,000	$176,501,000	$371,362,000	$346,945,000
Cash And Cash Equivalents	$226,651,000	$77,391,000	$170,201,000	$62,526,000
Inventory	-	$0	$38,323,000	$9,769,000
Current Deferred Assets	-	-	-	$0
Prepaid Assets	-	-	-	-
Debt
Total Debt	$5,957,000	$1,981,000	$4,237,000	$6,277,000
Long Term Debt And Capital Lease Obligation	$4,698,000	$463,000	$1,980,000	$4,237,000
Current Debt And Capital Lease Obligation	$1,259,000	$1,518,000	$2,257,000	$2,040,000
Liabilities
Total Liabilities Net Minority Interest	$27,386,000	$28,869,000	$84,022,000	$50,846,000
Total Non Current Liabilities Net Minority Interest	$4,698,000	$463,000	$1,980,000	$4,237,000
Current Liabilities	$22,688,000	$28,406,000	$82,042,000	$46,609,000
Payables And Accrued Expenses	$11,374,000	$16,896,000	$62,995,000	$29,338,000
Payables	$3,519,000	$2,939,000	$22,061,000	$6,257,000
Accounts Payable	$3,519,000	$2,939,000	$22,061,000	$6,257,000
Non Current Deferred Liabilities	-	-	-	$0
Other Current Liabilities	-	-	-	$4,596,000
Other Payable	-	-	-	$1,358,000
Tradeand Other Payables Non Current	-	-	-	-
Equity
Common Stock Equity	$305,259,000	$164,765,000	$433,432,000	$340,607,000
Total Equity Gross Minority Interest	$305,259,000	$164,765,000	$433,432,000	$340,607,000
Stockholders Equity	$305,259,000	$164,765,000	$433,432,000	$340,607,000
Gains Losses Not Affecting Retained Earnings	$404,000	$-92,000	$197,000	$-86,000
Other Equity Adjustments	$404,000	$-92,000	$197,000	$-86,000
Retained Earnings	$-751,427,000	$-606,692,000	$-304,949,000	$-354,220,000
Preferred Securities Outside Stock Equity	-	-	-	$0
Other
Ordinary Shares Number	$109,884,502	$68,629,738	$67,707,432	$66,512,011
Share Issued	$109,884,502	$68,629,738	$67,707,432	$66,512,011
Tangible Book Value	$305,259,000	$164,765,000	$433,432,000	$340,607,000
Invested Capital	$305,259,000	$164,765,000	$433,432,000	$340,607,000
Working Capital	$300,983,000	$161,026,000	$382,624,000	$335,524,000
Capital Lease Obligations	$5,957,000	$1,981,000	$4,237,000	$6,277,000
Total Capitalization	$305,259,000	$164,765,000	$433,432,000	$340,607,000
Additional Paid In Capital	$1,056,271,000	$771,542,000	$738,177,000	$694,906,000
Capital Stock	$11,000	$7,000	$7,000	$7,000
Common Stock	$11,000	$7,000	$7,000	$7,000
Long Term Capital Lease Obligation	$4,698,000	$463,000	$1,980,000	$4,237,000
Current Capital Lease Obligation	$1,259,000	$1,518,000	$2,257,000	$2,040,000
Pensionand Other Post Retirement Benefit Plans Current	$10,055,000	$9,992,000	$16,790,000	$15,231,000
Current Accrued Expenses	$7,855,000	$13,957,000	$40,934,000	$23,081,000
Net PPE	$5,491,000	$2,732,000	$6,411,000	$8,135,000
Accumulated Depreciation	$-1,554,000	$-1,359,000	$-1,628,000	$-540,000
Gross PPE	$7,045,000	$4,091,000	$8,039,000	$8,675,000
Leases	$154,000	$176,000	$176,000	$176,000
Construction In Progress	$19,000	$221,000	$589,000	$803,000
Other Properties	$5,181,000	$1,771,000	$3,725,000	$5,524,000
Machinery Furniture Equipment	$1,691,000	$1,923,000	$3,549,000	$2,172,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$90,328,000	$99,110,000	$201,161,000	$284,419,000
Finished Goods	-	$0	-	$937,000
Work In Process	-	$0	-	$1,681,000
Raw Materials	-	$0	-	$7,151,000
Preferred Stock	-	-	$0	$0

Fetched: 2026-05-30

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-123,481,000	$-167,804,000	$10,678,000	$-182,397,000
Operating Activities
Operating Cash Flow	$-123,343,000	$-167,647,000	$11,919,000	$-179,871,000
Cash Flow From Continuing Operating Activities	$-123,343,000	$-167,647,000	$11,919,000	$-179,871,000
Investing Activities
Capital Expenditure	$-138,000	$-157,000	$-1,241,000	$-2,526,000
Investing Cash Flow	$14,039,000	$75,654,000	$92,053,000	$-238,988,000
Cash Flow From Continuing Investing Activities	$14,039,000	$75,654,000	$92,053,000	$-238,988,000
Net Other Investing Changes	-	$-36,203,000	-	-
Financing Activities
Financing Cash Flow	$257,029,000	$348,000	$3,543,000	$431,789,000
Cash Flow From Continuing Financing Activities	$257,029,000	$348,000	$3,543,000	$431,789,000
Net Other Financing Charges	$252,952,000	$-1,784,000	$-3,451,000	$-2,847,000
Issuance Of Capital Stock	-	-	$0	$432,447,000
Net Preferred Stock Issuance	-	-	$0	$0
Preferred Stock Issuance	-	-	$0	$0
Net Common Stock Issuance	-	-	$0	$432,447,000
Common Stock Issuance	-	-	$0	$432,447,000
Other
End Cash Position	$227,636,000	$78,837,000	$170,920,000	$63,245,000
Beginning Cash Position	$78,837,000	$170,920,000	$63,245,000	$50,380,000
Effect Of Exchange Rate Changes	$1,074,000	$-438,000	$160,000	$-65,000
Changes In Cash	$147,725,000	$-91,645,000	$107,515,000	$12,930,000
Proceeds From Stock Option Exercised	$4,077,000	$2,132,000	$6,994,000	$2,189,000
Net Investment Purchase And Sale	$14,177,000	$112,014,000	$93,294,000	$-236,462,000
Sale Of Investment	$246,000,000	$344,000,000	$394,120,000	$179,411,000
Purchase Of Investment	$-231,823,000	$-231,986,000	$-300,826,000	$-415,873,000
Net PPE Purchase And Sale	$-138,000	$-157,000	$-1,241,000	$-2,526,000
Purchase Of PPE	$-138,000	$-157,000	$-1,241,000	$-2,526,000
Change In Working Capital	$-1,083,000	$-45,831,000	$-65,661,000	$-1,641,000
Change In Other Current Liabilities	$-1,162,000	$-2,256,000	$-2,041,000	$-917,000
Change In Other Current Assets	$1,730,000	$1,954,000	$1,568,000	$1,179,000
Change In Payables And Accrued Expense	$-6,018,000	$-78,912,000	$37,479,000	$27,906,000
Change In Accrued Expense	$-6,598,000	$-59,810,000	$21,597,000	$26,052,000
Change In Payable	$580,000	$-19,102,000	$15,882,000	$1,854,000
Change In Account Payable	$580,000	$-19,102,000	$15,882,000	$1,854,000
Change In Prepaid Assets	$3,984,000	$2,675,000	$-3,226,000	$-5,221,000
Change In Inventory	$0	$-9,253,000	$-73,129,000	$-9,769,000
Change In Receivables	$383,000	$39,961,000	$-24,744,000	$-14,819,000
Changes In Account Receivables	$359,000	$39,602,000	$-24,744,000	$-15,306,000
Other Non Cash Items	$-169,000	$37,161,000	-	-
Stock Based Compensation	$27,645,000	$33,038,000	$37,161,000	$21,714,000
Asset Impairment Charge	$0	$118,680,000	$0	-
Amortization Of Securities	$-5,526,000	$-9,856,000	$-9,940,000	$-2,056,000
Depreciation Amortization Depletion	$525,000	$904,000	$1,088,000	$487,000
Depreciation And Amortization	$525,000	$904,000	$1,088,000	$487,000
Depreciation	$525,000	$904,000	$1,088,000	$487,000
Net Income From Continuing Operations	$-144,735,000	$-301,743,000	$49,271,000	$-198,375,000
Income Tax Paid Supplemental Data	-	$708,000	$6,389,000	$27,000
Repayment Of Debt	-	-	$0	$0
Issuance Of Debt	-	-	$0	$0
Net Issuance Payments Of Debt	-	-	$0	$0
Net Long Term Debt Issuance	-	-	$0	$0
Long Term Debt Payments	-	-	$0	$0
Long Term Debt Issuance	-	-	$0	$0
Change In Interest Payable	-	-	$0	$0

Fetched: 2026-05-30